Literature DB >> 24936238

Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.

Qi Shi1, Shaoman Yin2, Stefan Kaluz3, Nanting Ni4, Narra Sarojini Devi2, Jiyoung Mun5, Danzhu Wang4, Krishna Damera4, Weixuan Chen4, Sarah Burroughs4, Suazette Reid Mooring4, Mark M Goodman6, Erwin G Van Meir7, Binghe Wang4, James P Snyder8.   

Abstract

Hypoxia inducible factors (HIFs) are transcription factors that activate expression of multiple gene products and promote tumor adaptation to a hypoxic environment. To become transcriptionally active, HIFs associate with cofactors p300 or CBP. Previously, we found that arylsulfonamides can antagonize HIF transcription in a bioassay, block the p300/HIF-1α interaction, and exert potent anticancer activity in several animal models. In the present work, KCN1-bead affinity pull down, (14)C-labeled KCN1 binding, and KCN1-surface plasmon resonance measurements provide initial support for a mechanism in which KCN1 can bind to the CH1 domain of p300 and likely prevent the p300/HIF-1α assembly. Using a previously reported NMR structure of the p300/HIF-1α complex, we have identified potential binding sites in the p300-CH1 domain. A two-site binding model coupled with IC50 values has allowed establishment of a modest ROC-based enrichment and creation of a guide for future analogue synthesis.

Entities:  

Keywords:  HIF arylsulfonamide inhibitors; KCN1; QSAR; binding model; hypoxia; p300; solid tumors

Year:  2012        PMID: 24936238      PMCID: PMC4056939          DOI: 10.1021/ml300042k

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

Review 1.  Surface plasmon resonance for proteomics.

Authors:  Nico J de Mol
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

3.  CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding.

Authors:  Roberto N De Guzman; Jonathan M Wojciak; Maria A Martinez-Yamout; H Jane Dyson; Peter E Wright
Journal:  Biochemistry       Date:  2005-01-18       Impact factor: 3.162

4.  Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.

Authors:  Suazette Reid Mooring; Hui Jin; Narra S Devi; Adnan A Jabbar; Stefan Kaluz; Yuan Liu; Erwin G Van Meir; Binghe Wang
Journal:  J Med Chem       Date:  2011-11-23       Impact factor: 7.446

5.  Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response.

Authors:  Sonja A Dames; Maria Martinez-Yamout; Roberto N De Guzman; H Jane Dyson; Peter E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

Review 6.  Genetic and hypoxic regulation of angiogenesis in gliomas.

Authors:  Balveen Kaur; Chalet Tan; Daniel J Brat; Dawn E Post; Erwin G Van Meir
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

7.  An essential role for p300/CBP in the cellular response to hypoxia.

Authors:  Z Arany; L E Huang; R Eckner; S Bhattacharya; C Jiang; M A Goldberg; H F Bunn; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

8.  Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.

Authors:  Dawn E Post; Narra Sarojini Devi; Zhenchao Li; Daniel J Brat; Balveen Kaur; Ainsley Nicholson; Jeffrey J Olson; Zhaobin Zhang; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

9.  Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression.

Authors:  Pedro C Lara; Marta Lloret; Bernardino Clavo; Rosa M Apolinario; Luis Alberto Henríquez-Hernández; Elisa Bordón; Fausto Fontes; Agustín Rey
Journal:  Radiat Oncol       Date:  2009-08-06       Impact factor: 3.481

10.  Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.

Authors:  Dawn E Post; Eric M Sandberg; Michele M Kyle; Narra Sarojini Devi; Daniel J Brat; Zhiheng Xu; Mourad Tighiouart; Erwin G Van Meir
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

View more
  10 in total

1.  Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma.

Authors:  Lei Dong; Shuo You; Qing Zhang; Satoru Osuka; Narra S Devi; Stefan Kaluz; Jalisa H Ferguson; Hua Yang; Guoliang Chen; Binghe Wang; Hans E Grossniklaus; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

Review 2.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

3.  Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.

Authors:  Jiyoung Mun; Adnan Abdul Jabbar; Narra Sarojini Devi; Shaoman Yin; Yingzhe Wang; Chalet Tan; Deborah Culver; James P Snyder; Erwin G Van Meir; Mark M Goodman
Journal:  J Med Chem       Date:  2012-07-24       Impact factor: 7.446

4.  Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway.

Authors:  Jalisa Ferguson; Zeus De Los Santos; Narra Devi; Erwin Van Meir; Sarah Zingales; Binghe Wang
Journal:  Bioorg Med Chem Lett       Date:  2017-03-01       Impact factor: 2.823

5.  Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.

Authors:  Shaoman Yin; Stefan Kaluz; Narra S Devi; Adnan A Jabbar; Rita G de Noronha; Jiyoung Mun; Zhaobin Zhang; Purushotham R Boreddy; Wei Wang; Zhibo Wang; Thomas Abbruscato; Zhengjia Chen; Jeffrey J Olson; Ruiwen Zhang; Mark M Goodman; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2012-08-24       Impact factor: 12.531

Review 6.  Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

Authors:  Erwin G Van Meir; Binghe Wang; Sarah K Burroughs; Stefan Kaluz; Danzhu Wang; Ke Wang
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

7.  KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Authors:  Wei Wang; Lin Ao; Elizabeth R Rayburn; Hongxia Xu; Xiangrong Zhang; Xu Zhang; Subhasree Ashok Nag; Xuming Wu; Ming-Hai Wang; Hui Wang; Erwin G Van Meir; Ruiwen Zhang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

8.  Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example.

Authors:  Yong Joon Kim; Stefan Kaluz; Anil Mehta; Emily Weinert; Shannon Rivera; Erwin G Van Meir
Journal:  Bio Protoc       Date:  2017-09-05

9.  Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.

Authors:  Stefan Kaluz; Qing Zhang; Yuki Kuranaga; Hua Yang; Satoru Osuka; Debanjan Bhattacharya; Narra S Devi; Jiyoung Mun; Wei Wang; Ruiwen Zhang; Mark M Goodman; Hans E Grossniklaus; Erwin G Van Meir
Journal:  Oncogene       Date:  2021-07-03       Impact factor: 9.867

Review 10.  Targeting Protein-Protein Interactions in the HIF System.

Authors:  Sarah E Wilkins; Martine I Abboud; Rebecca L Hancock; Christopher J Schofield
Journal:  ChemMedChem       Date:  2016-03-21       Impact factor: 3.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.